Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD‐L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer

BACKGROUND: We examined the current biomarker landscape in breast cancer when programmed death‐ligand 1 (PD‐L1) testing is integrated with comprehensive genomic profiling (CGP). MATERIAL AND METHODS: We analyzed data from samples of 312 consecutive patients with breast carcinoma tested with both CGP...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Huang, Richard S.P., Li, Xinyan, Haberberger, James, Sokol, Ethan, Severson, Eric, Duncan, Daniel L., Hemmerich, Amanda, Edgerly, Claire, Williams, Erik, Elvin, Julia, Vergilio, Jo‐Anne, Killian, Jonathan Keith, Lin, Douglas, Hiemenz, Matthew, Xiao, Jinpeng, McEwan, Deborah, Holmes, Oliver, Danziger, Natalie, Erlich, Rachel, Frampton, Garrett, Cohen, Michael B., McGregor, Kimberly, Reddy, Prasanth, Cardeiro, Dawn, Anhorn, Rachel, Venstrom, Jeffrey, Alexander, Brian, Brown, Charlotte, Pusztai, Lajos, Ross, Jeffrey S., Ramkissoon, Shakti H.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Cancer Diagnostics and Molecular Pathology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648336/
https://ncbi.nlm.nih.gov/pubmed/32869930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0449
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items